The nutraceuticals : a new therapeutic strategy in the management of digestive and respiratory disorders by G. Ciprandi et al.
The nutraceuticals: a new therapeutic strategy in the 
management of digestive and respiratory disorders
Giorgio Ciprandi1, Salvo Emanuele Aragona2, Lorenzo Drago3, Ignazio La Mantia4
1Allergy Clinic, Casa di Cura Villa Montallegro, Genoa, Italy; 2Center of Regenerative Medicine, Humanitas Mater Domini, 
Castellanza (VA), Italy; 3Microbiology Department, University of Milan, Milan, Italy; 4ENT Department, University of Ca-
tania, Catania, Italy
Summary. Nutraceuticals represents an intriguing challenge in clinical practice. They are currently used 
worldwide in all fields of Medicine. The present Supplement reports two Italian surveys concerning a pro-
biotic mixture employed in patients with chronic intestinal disorders and a Medical Device used in patients 
with upper respiratory diseases. These surveys were conducted on a group of Italian gastroenterologists and 
on a group of Italian otolaryngologists respectively. Both surveys demonstrated that these compounds may 
represent a useful therapeutic option in clinical practice. (www.actabiomedica.it)
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F o r e w o r d
The term ‘nutraceutical’ has been coined by Ste-
phen L. Defelice in 1989 (1). The use of this term, 
evaluated from frequencies in papers indexed in Pub-
Med, has progressively increased since 2000. However, 
there is no internationally recognized definition of a 
nutraceutical, and various confusing and contradictory 
definitions have appeared. In this regard, the European 
Nutraceutical Association defines nutraceuticals as 
“nutritional products which have effects that are rel-
evant to health, which are not synthetic substances or 
chemical compounds formulated for specific indica-
tions, containing nutrients partly in concentrated form” 
(2). Nutraceuticals are neither nutritious nor phar-
maceutical (3). However, nutraceuticals represent an 
interesting and exciting challenge in clinical practice. 
Actually, many doctors and patients look at comple-
mentary medicine as they scare the pharmacological 
compounds because of their adverse effects. At present, 
nutraceuticals are used in every field of Medicine.
On the basis of this background, this Supplement 
reports two surveys concerning the therapeutic effec-
tiveness and safety of two nutraceuticals, the first test-
ed in patients with chronic intestinal disorders and the 
second used in patients with upper respiratory diseas-
es), in clinical practice. These surveys have been con-
ducted on a group of Italian gastroenterologists and on 
a group of Italian otolaryngologists respectively. 
The first innovative product is an oral nutraceu-
tical containing a probiotic mixture with Lactobacillus 
plantarum LP01 (1 billion of living cells), Lactobacillus 
lactis subspecies cremoris LLC02 (800 millions of living 
cells), and Lactobacillus delbrueckii LDD01 (200 mil-
lions of living cells). The survey about this probiotic 
mixture included patients with chronic intestinal dis-
orders, patients undergoing bowel preparation, or pa-
tients undergoing abdominal surgery.
Probiotics are living microorganisms that confer a 
health benefit to the host when administered in ade-
quate amounts; when ingested, probiotics produce mi-
crobial transformation in the intestinal microbiota and 
exert several health-promoting properties, including 
maintenance of the gut barrier function and modula-
tion of the host immune system (4). Moreover, the ef-
fects of probiotic mixtures may be complementary (also 
referred to additive) or synergistic (5). In general, pro-
biotic strains produce growth factors that strengthen 
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the gut epithelium and antimicrobial-anti-inflamma-
tory mediators (e.g., short chain fatty acids, bacterioc-
ins, hydroperoxides, bile acids, and lactic acids) killing 
harmful microorganisms (6). As a consequence, their 
cellular components are released in the gut environ-
ment, activating immune responses by modulating the 
pro-inflammatory cytokines production and immuno-
globulin synthesis, besides of improving macrophage 
and lymphocytes activity (7). In addition, non-immu-
nological benefits associated to probiotics include the 
digestion and absorption processes, competition with 
potential pathogens for nutrients and intestinal adhe-
sion sites, pH alterations, agglutination of pathogenic 
microorganisms, and sequestration of metabolic toxins 
(8). Animal models and in vitro assays describe that 
probiotics also decrease the apoptosis, increase the 
mucus synthesis, tissue repair, redistribution and pro-
duction of tight junctions in gut epithelial cells, thus 
reducing the intestinal permeability and enhancing the 
barrier protection and function (9). However. It has to 
underline that the underlying mechanisms of probiot-
ics are dependent on the specific microbial strain and 
the effectiveness is also disease-specific. Thus, the pro-
biotic choice should be carefully oriented to a specific 
strain in a specific disease.
The second product is a Medical Device class II 
CE formulated as solution for aerosol. This innovative 
compound contains salso-bromo-iodine thermal water 
(spring of Medesano, PR, Italy), hyaluronic acid (HA), 
and grapefruit seed extracts. The salso-bromo-iodine 
thermal waters are very well known and appreciated for 
their positive effects in the treatment of upper respira-
tory tract infections, indeed it has been demonstrated 
that enhance mucociliary clearance, as well as improve 
the cough due to post-nasal drip (10). HA is a fun-
damental component of the connective tissue. HA is 
able to modulate inflammatory response, cellular pro-
liferation, and remodelling of extracellular matrix (11). 
Grapefruit seed extract exerts an antimicrobial activity 
(12). Therefore, the reported survey was conducted on 
patients suffering from acute, chronic or flare-up upper 
respiratory tract infections.
This Supplement contains also 3 clinical studies 
concerning: i) the use of visual analogue scale (VAS) 
in assessing the perception of antihistamines took by 
patients with allergic rhinitis, ii) the impact of to-
bacco smoke in allergic rhinitis, and iii) the relevance 
of sleep-disordered breathing (SDB) on oral health 
in children. The first study pertained the use of VAS 
as a parameter widely measured in the second survey, 
reinforcing its validity in clinical practice. The second 
study confirmed the negative impact of tobacco smoke 
on airways in patients suffering from allergic disorders. 
The last study demonstrated that SDB significantly 
affect oral wellbeing in childhood. Notably, as these 
conditions are chronic and frequently associated with 
inflammatory/infectious comorbidity, it may be fruit-
ful to combine pharmacological treatments with com-
plementary medicine, including thermal water, hyalu-
ronic acid, and food supplements, such as bromelain 
and grapefruit seed. Actually, complementary medi-
cine usually is associated with very few side effects and 
may be consequently assumed safely for long periods.
In conclusions, the current outcomes have a clini-
cal relevance as they were obtained in real-world set-
tings. There are also some implications considering the 
close link between upper and lower airways, so im-
provement of upper airways disorders may also ame-
liorate lower airways comorbidity (13,14). Therefore, 
nutraceuticals, including probiotics and plant-derived 
components, may represent a reliable therapeutic op-
tion in clinical practice.
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